IMNM Valuation - Is Immunome Inc Over or Undervalued?

Comprehensive analysis of Immunome Inc valuation metrics including P/E, P/B, P/S, and EV/EBITDA ratios

Updated April 15, 2026-6 min read-View Full Analysis

Current Stock Price

$22.90

Market Cap

$2.56B

Valuation Date

Apr 15, 2026

Valuation Verdict

Potentially Overvalued

Based on valuation multiples, IMNM appears expensive relative to fundamentals. 2 key metrics suggest premium pricing.

Key Valuation Metrics

These four fundamental valuation ratios help determine if IMNM is trading at a fair price relative to its earnings, assets, revenue, and cash flow generation.

P/E Ratio (Price-to-Earnings)

N/A

Not profitable or data unavailable

P/B Ratio (Price-to-Book)

High

3.86x

Premium to book value

Stock trades at 3.86x its book value per share

P/S Ratio (Price-to-Sales)

High

368.69x

High relative to sales

Market values each $1 of revenue at $368.69

EV/EBITDA

N/A

EBITDA data unavailable

How to Interpret These Metrics

P/E Ratio: Lower P/E often indicates better value, but compare against industry peers. High-growth companies typically have higher P/E ratios. Market average is 15-20x.

P/B Ratio: Values below 1.0 suggest the stock trades below its net asset value, which could indicate undervaluation or fundamental problems. Technology companies often trade at higher P/B ratios.

P/S Ratio: Useful for unprofitable companies or comparing revenue efficiency. Lower is generally better, but high-margin businesses can justify higher P/S ratios.

EV/EBITDA: Accounts for debt and excludes non-cash expenses, making it ideal for comparing companies with different capital structures. Values under 10x often indicate good value.

How IMNM Compares to Peers

What This Means for Investors

Premium Valuation Alert

Immunome Inc (IMNM) is trading at premium valuation multiples, suggesting the market has high expectations for future growth. While this doesn't automatically mean the stock will decline, it does indicate limited margin of safety. Investors should carefully evaluate whether the company's growth prospects justify the current valuation or if they're paying too much for the stock.

Bullish Considerations

Bearish Considerations

High premium to book value
Elevated price-to-sales ratio
Multiple metrics indicate overvaluation

Complete Your Analysis

Valuation is just one piece of the puzzle. Get the complete picture of IMNM with our comprehensive analysis tools.

Full Stock Analysis

Complete financials, charts, and metrics

Should I Buy IMNM?

AI-powered investment recommendation

Price Forecast

Future price targets and predictions

Analyst Ratings

Wall Street consensus and targets

Deep Valuation Analysis

DCF model and intrinsic value

Frequently Asked Questions

What is IMNM's P/E ratio and what does it mean?

IMNM has a P/E (Price-to-Earnings) ratio of N/A. This means investors are paying $N/A for every $1 of annual earnings. A lower P/E generally suggests better value, but it's important to compare against industry peers and growth prospects. The market average P/E is typically 15-20x.

Is IMNM stock overvalued or undervalued?

Based on our analysis of key valuation metrics (P/E, P/B, P/S, EV/EBITDA), IMNM appears potentially overvalued. Based on valuation multiples, IMNM appears expensive relative to fundamentals. 2 key metrics suggest premium pricing. However, valuation is just one factor to consider alongside growth prospects, competitive position, and market conditions.

What is a good P/E ratio for IMNM?

There's no single "good" P/E ratio as it varies by industry and growth stage. For Immunome Inc, compare the current P/E of N/A against: (1) Industry peers, (2) Historical average P/E for IMNM, (3) Expected earnings growth rate. High-growth companies often justify higher P/E ratios, while mature companies typically trade at lower multiples.

How do I use valuation ratios to make investment decisions?

Valuation ratios are screening tools, not buy/sell signals. Use them to: (1) Compare IMNM against competitors, (2) Identify potential over/undervaluation, (3) Understand what you're paying for earnings, assets, or sales. Combine valuation analysis with fundamental research, growth prospects, and technical analysis for comprehensive decision-making.

What is EV/EBITDA and why does it matter?

EV/EBITDA (Enterprise Value to EBITDA) is N/A for IMNM. This ratio is useful because it accounts for debt and excludes non-cash expenses, making it better for comparing companies with different capital structures. Lower EV/EBITDA generally indicates better value. It's particularly useful for comparing companies in capital-intensive industries.

Disclaimer: This valuation analysis is for informational and educational purposes only and should not be considered investment advice. Valuation metrics are just one factor in investment decisions. Always conduct comprehensive research and consult with a qualified financial advisor before making investment decisions. Past performance and current valuations do not guarantee future results.